The spectrum of bone phenotypes reported in CKD–MBD models may reflect the differing serum PTH levels at the point of study, as progressive SHPT is linked with different effects on bone quality and structure (Miller et al. 1998). This evidence concerns the gene PTH and chronic kidney disease.